NVO Novo Nordisk A/S

52.52
-0.16  -0%
Previous Close 52.68
Open 52.63
Price To Book 16.01
Market Cap 124,202,079,875
Shares 2,364,853,006
Volume 780,385
Short Ratio 4.19
Av. Daily Volume 1,391,938
Stock charts supplied by TradingView

NewsSee all news

  1. New international study: The hidden burden of diabetes on family members revealed

    New international study shows 64 per cent of family members of peoplewith diabetes are worried or anxious about the risk of low blood sugar MISSISSAUGA, ON, Sept. 10, 2019 /CNW/ - People

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced September 20, 2019.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 trial to be initiated 4Q 2019.
Concizumab
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial initiated 2Q 2019.
Somapacitan (NN8640)
Growth Hormone Deficiency (GHD)
Phase 2 data released 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Semaglutide
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
N8-GP
Hemophilia A
Phase 2 trial initiated 1Q 2019.
AM833
Obesity
Phase 1 data due 4Q 2019
LAIsema
Type 2 diabetes
Phase 1 data due 4Q 2019.
Tri-agonist 1706
Obesity
Phase 1 data due 4Q 2019.
PYY 1562
Obesity

Latest News

  1. New international study: The hidden burden of diabetes on family members revealed

    New international study shows 64 per cent of family members of peoplewith diabetes are worried or anxious about the risk of low blood sugar MISSISSAUGA, ON, Sept. 10, 2019 /CNW/ - People